BACKGROUND: @entity924 is the most common @entity74 . The etiology is still uncertain, and the disorder poses many therapeutic problems. In a few clinical studies, analgesic effects of high molecular weight hyaluronan (HMW @entity15773 ) injections were observed, but the underlying mechanisms were not elucidated. In the present study, we analyzed the therapeutic effects of hyaluronan injections for @entity924 in an animal model. METHODS: We made the @entity924 @entity35 model using a rodent treadmill machine. @entity35 with @entity924 were injected with HMW @entity15773 ( @entity15773 group), normal saline ( @entity7031 group), or nothing (control group) into the space between the patellar tendon and the fat pad bilaterally, or were injected with HMW @entity15773 into the right knees and with saline to the left knees ( @entity15773 / @entity7031 group), 5 times every 4  days. To assess the @entity158 -relieving effect of @entity15773 , the spontaneous locomotor activities at night (12  h) and weight bearing of hind paws were measured every day. Histological sections of the patellar tendon stained with @entity1710 - @entity1711 or prepared by TdT-mediated @entity1977 nick end labeling were microscopically analyzed. RESULTS: The number of spontaneous locomotor activities in the @entity15773 group was significantly larger than those in @entity7031 or control groups, and in the @entity15773 group they recovered up to a healthy level. The percent weight distribution of the right hind paws was significantly increased along with the number of injections. On histologic examinations, the numbers of microtears, laminations, or apoptotic cells in the patellar tendons in the @entity15773 group were significantly lower than those in the @entity7031 or the control groups. CONCLUSIONS: The injections of HMW @entity15773 were effective for @entity158 relief and for partial restoration of the patellar tendon in our @entity924 @entity35 model, and thus may become an effective therapeutic modality for the disease.

Therapeutic effects of high molecular weight hyaluronan injections for XXXX in a @entity35 model.

@entity1711 :: ('MESH:D004801', 'Chemical') :: ['eosin'] @entity924 :: ('MESH:D052256', 'Disease') :: ['Tendinopathy', 'tendinopathy'] @entity15773 :: ('MESH:C537629', 'Disease') :: ['HA'] @entity1977 :: ('CHEBI:17625', 'Chemical') :: ['dUTP'] @entity7031 :: ('MESH:D056770', 'Disease') :: ['NS'] @entity1710 :: ('MESH:D006416', 'Chemical') :: ['hematoxylin'] @entity74 :: ('MESH:D030342', 'Disease') :: ['tendon disorder'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity35 :: ('10116', 'Species') :: ['rat', 'Rats']
@entity924 :: (MESH:D052256,Disease) :: ['tendinopathy']
